Abstract Number: 1673 • ACR Convergence 2020
Principles of Pediatric Lupus Nephritis in a Contemporary Multi-Center Cohort
Background/Purpose: Lupus nephritis (LN) is a well-established and life-threatening manifestation of systemic lupus erythematosus (SLE) that is more common in children than adults. The demographics…Abstract Number: 1692 • ACR Convergence 2020
Poor Physical Activity Levels and Cardiorespiratory Fitness Among Patients with Childhood-Onset Takayasu Arteritis in Remission
Background/Purpose: Childhood-onset Takayasu Arteritis (c-TA) is a rare, granulomatous, chronic large-vessel vasculitis that involves mostly the aorta and its major branches with a high mortality…Abstract Number: 0608 • ACR Convergence 2020
Patient and Parent Perspectives in a Academic Pediatric Rheumatology Transition Clinic
Background/Purpose: In November 2018 we initiated a transition clinic called ACCORD (Adult Center for Childhood Onset Rheumatic Disease). Our unique structure integrates an adult rheumatologist…Abstract Number: 0734 • ACR Convergence 2020
Differences and Similarities Between down Syndrome-associated Arthritis and Juvenile Idiopathic Arthritis in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Background/Purpose: Down syndrome-associated arthritis (DA) is under-recognized with delay in diagnosis (1). The majority of those with DA present with polyarticular, rheumatoid factor (RF) and…Abstract Number: 1166 • ACR Convergence 2020
Use of Rituximab to Treat COPA Syndrome: A Multi-Institutional Cohort
Background/Purpose: Coatomer protein complex subunit α (COPA) syndrome is a rare genetic multisystem autoimmune disorder inherited in an autosomal dominant manner. Onset typically occurs in…Abstract Number: 1495 • ACR Convergence 2020
Tofacitinib for the Treatment of Patients with Juvenile Idiopathic Arthritis: An Interim Analysis of Data up to 5.5 Years from an Open-label, Long-term Extension Study
Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for JIA. We report the safety, tolerability, and efficacy of tofacitinib in patients (pts)…Abstract Number: 1674 • ACR Convergence 2020
Pediatric and Adolescent One Year Protocol Kidney Biopsies Should Be Performed, Even in Patients with Complete Remission of Their Lupus Nephritis
Background/Purpose: The value of one-year protocol kidney biopsies in children who have proliferative lupus nephritis (LN) is unclear, particularly in patients who meet CARRA criteria…Abstract Number: 1693 • ACR Convergence 2020
Evaluation of B-cell Depletion with Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease
Background/Purpose: Rituximab is standard therapy for autoimmune brain disease (ABD) including autoimmune encephalitis (AE) and Neuromyelitis Optica Spectrum Disease (NMOSD). Recommendations for continuing concurrent intravenous…Abstract Number: 0634 • ACR Convergence 2020
Influenza Knowledge and Barriers to Vaccination in Immunosuppressed Patients in the Pediatric Rheumatology Clinic
Background/Purpose: Many pediatric rheumatology patients are at increased risk of influenza due to immunosuppressive medication use. Annual influenza vaccination is recommended for all children by…Abstract Number: 0735 • ACR Convergence 2020
Paediatric Sarcoidosis: Phenotype of a Retrospective Cohort of Biopsy-proven Patients
Background/Purpose: Paediatric sarcoidosis is a multisystemic inflammatory condition characterised by the formation of non-caseating granulomata that may lead to end-organ damage. Diagnosis is challenging as…Abstract Number: 1167 • ACR Convergence 2020
Capturing the Range of Disease Involvement in Localized Scleroderma: The Total Morbidity Score
Background/Purpose: Localized scleroderma (LS) is a chronic inflammatory and fibrosing disease that causes both cutaneous and extracutaneous (EC) damage. EC involvement (ECI) is common in juvenile…Abstract Number: 1509 • ACR Convergence 2020
Leukocyte Telomere Length and Childhood Onset of Systemic Lupus Erythematosus in the Black Women’s Experiences Living with Lupus (BeWELL) Study
Background/Purpose: Childhood-onset SLE is generally more aggressive than adult-onset SLE. Leukocyte telomere length (LTL) has been posited to reflect immune system aging. Short LTL in…Abstract Number: 1676 • ACR Convergence 2020
Neuropsychiatric Involvement in Juvenile-onset Systemic Lupus Erythematosus (JSLE): Data from the UK JSLE Cohort Study
Background/Purpose: Juvenile-onset systemic lupus erythematosus (JSLE) is a rare autoimmune/inflammatory disease, accounting for up to 20% of SLE cases. Though clinically similar to adult-onset disease,…Abstract Number: 1694 • ACR Convergence 2020
Risk Factors Associated with Pneumocystis Jirovecii Pneumonia in Juvenile Myositis in North America
Background/Purpose: Pneumocystis jirovecii pneumonia (PJP) is associated with significant morbidity and mortality in adult myositis patients; however, few studies have examined PJP in juvenile myositis…Abstract Number: 0712 • ACR Convergence 2020
Switching from Reference to Biosimilars Does Not Reduce Efficacy and Safety in Juvenile Idiopathic Arthritis
Background/Purpose: Limited data about the use of biosimilar are available in children with Juvenile Idiopathic Arthritis (JIA). To evaluate the long-term efficacy and safety of switching…
- « Previous Page
- 1
- …
- 39
- 40
- 41
- 42
- 43
- …
- 52
- Next Page »